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Abstract Gene expression of human immunodeficiency virus 
(HIV) depends on a host cellular transcription factors including 
nuclear factor-gB (NF-~B). The involvement of reactive oxygen 
intermediates (ROI) has been implicated as intracellular 
messengers in the inducible activation of NF-~,B. In this study, 
we compared the efficacy of two antioxidants, ct-lipoic acid (LA) 
and N-acetylcysteine (NAC), which are widely recognized NF- 
~B inhibitors. Here, we demonstrate that LA has a more potent 
activity in inhibiting NF-gB-mediated gene expression in THP-1 
cells that have been stably transfected with a plasmid bearing a 
hygromycin B resistance gene under the control of HIV-I long 
terminal repeat (LTR) promoter. The spontaneous activation of 
NF-gB in this cell culture system leads to expression of the 
hygromycin phosphotransferase gene hence rendering the cells 
resistance to hygromycin B. In this study, the effect of the test 
compounds against transcriptional activity of HIV-1 LTR was 
evaluated based on the degree of cellular toxicity due to the 
inhibitory activity on the expression of hygromycin B resistance 
gene in the presence of hygromycin B. We also found that 0.2 
mM LA could cause 40% reduction in the HIV-1 expression 
from the TNF-~-stimulated OM 10.1, a cell line latently infected 
with HIV-1. On the other hand, 10 mM NAC was required to 
elicit the same effect. Furthermore, the initiation of HIV-1 
induction by TNF-~ was completely abolished by 1 mM LA. 
These findings confirm the involvement of ROI in NF-gB- 
mediated HIV gene expression as well as the efficacy of LA as a 
therapeutic regimen for I-IIV infection and acquired immunode- 
ficiency syndrome (AIDS). Moreover, this study validates the 
applicability of our present assay system which we primarily 
designed for the screening of candidate drugs against HIV-1 gene 
expression. 
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1. Introduction 
c~-Lipoic acid (LA), the oxidized form of 6,8-dimercapto- 
octanoic acid and its reduced form, dihydrolipoic acid 
(DHLA) have been gaining interest in the quest for an effica- 
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long terminal repeat; GSH, reduced glutathione; MTT, 3(4,5- 
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cious drug for the treatment of a wide variety of disorders 
that are mediated by reactive oxygen intermediates (ROI). LA 
is known to be reduced when it is incorporated into the cells 
in the form of DHLA. This LA/DHLA redox couple has been 
shown to have potent antioxidant abilities as investigated in
cases of human immunodeficiency virus (HIV) infection [1], 
diabetes [2], diabetic polyneuropathy [3,4] and dermatitis [5]. 
LA and DHLA have also been observed to have neuropro- 
tective capacity against direct and indirect excitotoxic insults 
[6], as well as protective ffect toward oxidative hemolysis of 
human erythrocytes [7]. These documented effects of LA and 
DHLA have been mainly attributed to their intrinsic free rad- 
ical-scavenging property [2,6-9]. It has been investigated by 
Matsugo et al. [8] that the hydroxyl radical quenching activity 
of LA is a function of the disulfide bond in the dithiolane ring 
structure of the compound. It has also been postulated that 
the anti-inflammatory action of LA is due to its ability to 
suppress nitric oxide production [2]. Another proposed mech- 
anism of action of LA is the antioxidant's ability to chelate 
transition metals [3,8]. Other investigators further reported 
that LA can elevate the total level of the endogenous antiox- 
idant, reduced glutathione (GSH), in some tissues and cell 
lines [4,6]. 
N-Acetylcysteine (NAC) is a precursor of GSH and is also 
used as a nontoxic drug widely prescribed as a mucolytic 
agent and antidote against drug-induced hepatotoxicity [10]. 
It has also been used clinically to treat acetaminophen toxicity 
[11]. Results of laboratory investigations have also implied the 
usefulness of NAC therapy in cases of HIV infection as well 
as inflammatory and oxidative stress-mediated pathologies in- 
cluding acute respiratory distress syndrome (ARDS), toxic 
and septic shock, porphyria and cerebral malaria [12] and 
melanoma [10]. It is believed that these therapeutic values of 
NAC are due to its direct scavenging actions on ROI [12-14]. 
On the other hand, others postulate that the effect of NAC 
could not be ascribed to its reducing activity but to the in- 
direct effects on another cellular reducing system such as that 
of thioredoxin [15]. Moreover, it has been recognized that 
NAC, with its ability to penetrate the cell membrane, gets 
rapidly deacetylated to L-cysteine by N-acetylases present in 
various organs, thereby replenishing the intracellular cysteine 
required to produce GSH [4,10-13,16,17]. GSH is the major 
intracellular thiol, which comprises > 90% of the cellular non- 
protein thiols and an ROI scavenger present in all eukaryotic 
cells [10 12]. 
The therapeutic values of LA and NAC in acquired immu- 
nodeficiency syndrome (AIDS) and HIV infection have been 
looked into, mainly, in the light of redox regulatory mech- 
anism that is involved in the activation of an inducible cellular 
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transcription factor, nuclear factor-~B (NF-~cB) [4,11- 
13,15,16]. 
In the present study, we have further confirmed the antiox- 
idant property of LA and NAC, including their role in inhi- 
biting HIV-1 gene expression using recombinant THP-1, a 
CD4 + monocyte-macrophage cell clone that has been stably 
transduced with a plasmid containing a phosphotransferase 
gene under the control of HIV-I LTR. The findings were 
analyzed based on the results of a colorimetric ytotoxicity 
assay using 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazo- 
lium bromide (MTT) dye. The MTT assay utilized in this 
investigation was our modification of the original protocol 
of Mosmann [18] which we designed and established as a 
screening method for anti-Tat drugs [19]. To further support 
the findings with the current assay system, we have confirmed 
the effect of LA and NAC on viral p24 antigen expression in 
the culture fluid of TNF-c~-stimulated OM 10.1 cells, a macro- 
phage cell line that is latently infected with HIV-1 [20]. 
2. Materials and methods 
2.1. Cell lines and plasmids 
For this series of experiments, THP-1, a CD4 + monocyte-macro- 
phage cell line, was used. pKO plasmid was used to render the trans- 
fected cells resistant to hygromycin B. A detailed escription of pKO 
plasmid construction has been presented previously [19]. However, for 
this particular experiment, he pKO plasmid was cut by XbaI as to 
render Tat nonfunctional. Thus, the cells were resistant to hygromycin 
B, solely dependent on host cellular transcription factors, in particu- 
lar, NF-~cB owing to the presence of its binding sites in the HIV-1 
LTR promoter (Fig. IA). 
The HIV-I p24 antigen detection was carried out with the culture 
supernatants of OM 10.1, a monocyte-macrophage cell line that is 
latently infected with HIV-I [20] which was a gift from Dr. R.F. 
Schinazi of Emory University, VA Medical Center, GA, USA. 
All cells were maintained in culture medium prepared from RPMI 
1640 supplemented with 10% fetal calf serum (FCS). 
2.2. Preparation of recombinant cells 
THP-1 recombinant cells, referred to in this paper as T-Xba, were 
prepared by transfection of the Xbal-digested pKO plasmid [19]. Elec- 
troporation was carried out with Electro Cell Manipulator 600 (BTX, 
San Diego, CA, USA) under the following conditions: 2950 laF ca- 
pacitance and 0.5 kV/cm field strength using 2-mm gap BTX cuvette 
containing 4X 106 cells resuspended in 200/al serum-free RPMI 1640 
with 10 mM dextrose and 0.I mM dithiothreitol. After 24 h incuba- 
tion, cell viability was measured using trypan blue exclusion method. 
Stable transfectants were obtained by long-term cultivation in the 
presence of 300 ~g/ml hygromycin B. Thereafter, cells were main- 
tained in RPMI 1640 supplemented with 10% FCS and 300 ~tg/ml 
hygromycin B (Sigma Chemical Co., St. Louis, MO, USA). As dic- 
tated by the restriction site of the transfected plasmid, the expression 
of the hygromycin phosphotransferase gene is dependent on host 
transcription factors, particularly NF-~cB [19]. 
2.3. Anti-NF-r~B MTT assay 
The test for the activity of LA and NAC on HIV-1 gene expression, 
referred to in this paper as anti-NF-~cB MTT assay, was done accord- 
ing to the original cytotoxicity assay described in Kira et. al. [19], with 
some modifications. Carbenicillin was included to serve as negative 
control. Briefly, two-fold serial dilution of the drugs in 50-tal amounts 
was distributed onto triplicate wells of sterile flat-bottomed 96-well 
microtiter plates. In addition, 500 Ixg/ml final concentration of either 
hygromycin B (test) or culture medium (control), in 50-~tl amounts, 
was dispensed to designated wells. The cells were then seeded at a 
density of 1 x 105/ml in 1004al amounts. Incubation was carried out in 
an atmosphere of 5% CO2 in air humidified at 37°C. On the sixth day 
of incubation, cell viability was quantified by adding 25 lal MTT dye 
to the cultures and allowing it to be reacted upon for 2 h by the 
mitochondrial dehydrogenases generated by viable cells. The resulting 
formazan crystals were dissolved in DMSO and Sorensen's glycine 
buffer. Absorbance was measured at 540/690 nm. Throughout he 
study, all the experiments were carried out in triplicate. Experimental 
variations of cytotoxicity values of the samples were within _+ 5%,. 
Interpretation of results was done by determining the effective (E) 
and control (C) doses of the drugs and evaluating the relative fficacy 
of the test compound using E:C ratios. This has been described in 
detail in our previous paper [19]. Briefly, 'E' refers to that which 
causes cytotoxicity due to the effect of compound against NF-~cB, 
that is, cell death in the presence of both the test drug and hygro- 
mycin B. 'C' reflects the nonselective cytotoxicity by test compounds, 
that is, the cell-killing effect of the test drug in the absence of hygro- 
mycin B. An E:C ratio value less than 1.0 indicates that the test 
compound has a selective cytotoxicity due to the inhibition of the 
HIV-I promoter activity. The concentration of the test compound 
showing an E:C ratio value of 0.5 represents its 50% effective con- 
centration (EC.~t0. If the ECs0 value of a test compound is close to the 
concentration of 50% nonselective cytotoxicity, the compound is not 
recommended asa candidate drug because of the narrow therapeutic 
window. 
2.4. p24 antigen assay 
The viral p24 antigen level in the culture supernatant of OM 10.1 
was measured using a commercial kit, Abbott ~ HIVAG-1 B1A010 
(Abbott Park, IL, USA), a sandwich solid phase enzyme immunoas- 
say (EIA) in bead format. The samples were harvested from OM 10.1 
cultures which have been stimulated for 72 h with 2 ng/ml TNF-tx 
(Boehringer Mannheim Biochemica, Mannheim, Germany). The p24 
antigen concentration was determined based on a curve constructed 
from the standard p24 antigen. 
3. Results 
3.1. Establishment of  hygromycin B-resistant cells 
After transfection of the XbaI-digested pKO plasmid into 
CD4 + THP-1, cultures were maintained in medium containing 
300 ~tg/ml hygromycin B to select hygromycin B-resistant 
cells. To confirm the level of cellular resistance to hygromycin 
B, the cells were maintained for 6 days in culture containing 
varied concentrations (0-3000 ~tg/ml) of the antibiotic and cell 
viability was measured by MTT assay. As seen in Fig. 1B, 
THP-1 parental cells demonstrated a 26% fall in their survival, 
expressed as percent of the control, at 125 ~tg/ml hygromycin 
B. It then reached an almost undetectable vel starting at 500 
~tg/ml at which concentration, recombinant T-Xba cells main- 
tained 82% viability. Thus, it was decided that 500 ~tg/ml 
hygromycin B is suitable for the actual drug screening assay. 
Even at the highest concentration tested (3000 [tg/ml), T-Xba 
showed some resistance to hygromycin B, with 20% of them 
remaining viable. These results confirmed the successful trans- 
fection and the constitutive xpression of the hygromycin B 
phosphotransferase g ne in T-Xba cells. 
3.2. Evaluation of  LA and NAC by anti-NF-w,B MTT assay 
Using the recombinant T-Xba cells which constitutively ex- 
press the hygromycin B resistance gene, we investigated the 
effects of known NF-~B inhibitors, LA and NAC. Fig. 2 
shows the representative r sults of anti-NF-~B MTT assay 
depicting the nonselective cytotoxicity by test compounds 
and their corresponding specific cytotoxicity due to their gen- 
uine effect on NF-~:B-dependent gene expression. Carbenicil- 
lin, a 13-1actam antibiotic agent was used as a negative control. 
T-Xba cells, at a density of 104 per well were treated with 
serial two-fold dilutions (1920 to 7.5 ~tg/ml) of the test drugs 
in the presence or absence of 500 ~tg/ml hygromycin B. Cell 
viability was quantitated on day 6 of treatment. As shown in 
Fig. 2A, the 50% effective dose of LA was found to be 267 ~tg/ 
ml (1.29 mM), while the 50% nonselective cytotoxic dose was 
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750 gg/ml (3.6 mM). In contrast, NAC did not induce selec- 
tive cell killing. It was not able to bring the level of hygro- 
mycin cytotoxicity to 50% even at the highest concentration 
tested, 1920 gg/ml (12 raM). Although there was an observed 
50% control dose for NAC at 960 gg/ml (5.9 mM), this seems 
to be an artifactual cell killing as the cell viability at 1920 lag/ 
rnl increased considerably. 
To better evaluate the effect of the drugs, E:C ratio at 
different drug concentrations was calculated based on their 
selective and nonselective cytotoxicities. As demonstrated in 
Fig. 2B, LA is expected to be effective at concentrations above 
190 ~tg/ml (0.9 raM), the calculated ECs0 dose. LA has a 
relatively wide therapeutic window as its 50% nonselective 
cytotoxicity dose which was determined to be 750 gg/ml (3.6 
mM) is 4-times as high as the calculated ECs0 value. The 
therapeutic window for NAC could not be determined since 
the ECs0 was not reached. However, as seen in the p24 anti- 
gen detection assay in the foregoing section, NAC can be an 
effective NF-~B inhibitor when used at much higher concen- 
trations than what was used for the MTT assay. 
3.3. Evaluation of LA and NAC using p24 antigen assay 
To substantiate he above findings, we used varying con- 
centrations of LA and NAC to examine their inhibitory effect 
on HIV-I p24 antigen expression i OM 10.1 cells. In addition 
to pretreatment with LA and NAC, test cultures were also 
exposed to a uniform concentration of TNF-e~ (2 ng/ml) to 
stimulate NF-~cB activation. Cell-free culture supernatants 
were used for the assay. As shown in Fig. 3, there was a 
detectable amount of p24 antigen (between the range of 0.5 
2 ng/ml) in the supernatant of OM 10.1 cell cultures which 
were not stimulated with TNF-c~, indicating low-level expres- 
sion of structural proteins and production of virions in these 
chronically infected cells. However, there was no evident in- 
hibitory effect of LA and NAC on the viral antigen expression 
from the unstimulated OM 10.1 cells when a set of controls, 
that is, incubated with varied concentrations of the two anti- 
oxidants, was run in parallel with the antioxidant-pre-treated 
and TNF-e~-stimulated cells. 
The observed low-level expression of p24 antigen appears to 
reflect the actual atency period occurring between HIV infec- 
tion and the development of full-blown AIDS wherein the 
virus exists in a proviral DNA form which is integrated within 
the host genomic DNA though lacking full transcriptional 
activity [21,22]. The augmentation of virus expression in 
chronically infected cells can be achieved by treatment with 
cytokines uch as TNF which is associated with the induction 
of a nuclear factor(s) binding to the NF-~B sites in the HIV-1 
LTR [11,21,23]. In fact, TNF-c~ is considered to play a critical 
role in the pathogenesis of AIDS as its level in HIV-infected 
individuals has been found to be considerably increased [11]. 
Thus in this experiment, he p24 antigen expression was 
efficiently augmented upon treatment with 2 ng/ml TNF-e~, 
which was dramatically inhibited by LA or NAC. Greater 
than 1 mM LA was found to completely block HIV-1 p24 
antigen induction thereby bringing p24 antigen levels to the 
baseline. Approx. 40% reduction in p24 antigen production 
was observed in cultures which were TNF-e~-stimulated and 
pretreated with 0.2 mM LA as compared to TNF-c~-stimu- 
lated cells but were not pretreated with LA. In contrast, it 
required 50-times as much NAC to cause a similar effect (38% 
reduction). These findings upport he results of the anti-NF- 
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Fig. 1. Screening system for NF4cB inhibitors using recombinant 
THP-I ceils. (A) The DNA segment containing the transcription 
unit expressing the hygromycin phosphotransferase (hygromycin B 
resistance) gene under the control of HIV-I LTR. The DNA fag- 
ment of XbaI-restricted pKO plasmid [19] was transfected into 
THP-I human monocyte/macrophage cell line for the preparation of 
T-Xba recombinant clone. (B) Hygromycin resistance profile of 
THP-1 parental cells (closed bars) and T-Xba recombinant clone 
(cross-hatched bars). Cell viability, expressed as percent of negative 
control (no hygromycin B treatment), was measured by MTT assay 
after one week incubation of cells with varying concentrations of 
hygromycin. 
~:B MTT assay (Fig. 2) in which LA was found to have a 
strong inhibitory effect while NAC was not found to be as 
effective. These results were reproducible and essentially the 
same observations were obtained over three times. Addition- 
ally, we have also examined the effects of other compounds 
known to block NF-~B including pentoxyphillin and sodium 
salicylate (data not shown). Among these compounds we ex- 
amined, LA was found to be the most effective. 
4. Discussion 
Data demonstrated in this study clearly indicate the feasi- 
bility of our test system in screening reagents that block HIV- 
1 gene expression. In the current assay, the promoter activity 
of HIV-1 LTR was examined as to the extent of expression of 
the hygromycin B phosphotransferase gene that endows cells 
with resistance to the toxicity of the antibiotic. The MTT 
assay used in this study is a modification of the test system 
described in our previous paper [19]. The pKO plasmid then 
used was cut by XbaI prior to transfection i this experiment 
to render Tat non-functional while leaving the NF-~cB-de- 
pendent HIV-1 LTR promoter intact. Thus, in this study, 
the assay was redesigned to screen inhibitors of NF-~cB and 
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Fig. 2. Effects of LA and NAC on HIV-1 LTR-directed hygromycin resistance in T-Xba cells. (A) T-Xba cells were treated with varying con- 
centrations of LA and NAC in the presence (o) or absence (©) of 500 gg/ml hygromycin B. Carbenicillin (CC) was used as a negative control. 
ECs0 represents 50%, effective concentration. (B) The effect-to-control (E:C) ratio values for each compound. The definition of E:C ratio was 
described previously as considering both the non-selective intrinsic ytotoxicity of a test compound and the selective effect of blocking the ex- 
pression of hygromycin resistant gene [19]. An E:C ratio less than 1 is an indication of an effective inhibitory action of the drug on HIV-1 
gene xpression i this assay system. 
possibly of other host transcription factors by measuring the 
level of cell viability in T-Xba recombinant host ceils. By 
using 500 ~tg/ml hygromycin B, it was assured that the killing 
of T-Xba cells was due to the genuine ffect of either LA or 
NAC since prior to the actual screening assay, such concen- 
tration was found to cause almost complete killing of THP-1 
parental cells while approx. 80% of T-Xba recombinant cells 
remained viable. 
To provide an additional measure of test validity, control 
cultures, that is, cells exposed to drugs but not to hygromycin 
B, were run in parallel with test cultures. Results represented 
the nonselective cytotoxicity of the drug and, therefore, were 
excluded in the calculation of E:C ratios [19]. ECs0 values 
were also determined to compare the degree of anti-HIV-1 
activities among the test drugs. We demonstrated here that 
LA exerted a stronger inhibitory effect against NF-~cB-de- 
pendent HIV-I gene expression compared to NAC. ECs0 val- 
ue was calculated to be 0.9 mM for LA, while it could not be 
determined for NAC because of its higher nonselective cyto- 
toxicity. This was further confirmed by the results of the p24 
antigen assay in which it required 50-times as much NAC to 
cause the same inhibitory action as LA. 
There are several advantages of our recommended screening 
test compared to other methods. Specifically, it offers the ad- 
vantages of being free from handling infectious virions and 
radioactive materials. It is also simple and gives reproducible 
results. The semi-automated spectrophotometric quantitation 
and subsequent computerized data processing makes the test 
easy to perform. These features make this assay suitable for 
complete automation for mass screening of potentially useful 
anti-HIV drugs. 
Using this new system, we could confirm the earlier eports 
of the efficacy of LA and NAC [1-7,10-16]. LA and NAC 
have been shown to block the NF-~B-dependent gene expres- 
sion by interfering with the signal transduction cascade lead- 
ing to the activation of NF-~B [11-17]. It has been well es- 
tablished that the NF-~B activation cascade is redox 
regulated. There is a large body of evidence that ROI serve 
as common messengers in the activation of NF-~B. Both 
agents were found to exert an inhibitory effect on NF-~B- 
dependent HIV-1 gene expression as evidenced by the de- 
creased resistance to hygromycin B (Fig. 2) and the inhibition 
of viral p24 induction upon TNF stimulation of OM 10.1 cells 
(Fig. 3). LA was found to have an advantage over NAC as its 
potency was evident at much lower concentrations. The mech- 
anism of action of both compounds i known to be through 
direct free radical scavenging actions on ROI. However, while 
NAC is believed to inhibit NF-~B and HIV replication by 
replenishing intracellular cysteine required to produce GSH 
[10-12], LA, on the other hand, has the ability to increase 
the total intracellular thiol levels [4,6]. The intracellular 
build-up of the oxidized LA, DHLA and increase in GSH 
levels due to E.A administration has been postulated to shift 
the redox status of the cell thus conceivably blocking the ROI- 
mediated NF-~cB activation. These observations together with 
the earlier observations by Baur et al. [24] using the acute 
HIV-1 infection system suggested the clinical usefulness of 
LA in the treatment of AIDS and its related conditions. 
In conclusion, we have reestablished the efficacy of LA and 
NAC, as measured by anti-NF-~B MTT and p24 antigen 
assays. Moreover, we have confirmed the applicability of the 
currently prescribed anti-NF-~B MTT assay. Thus, it can be 
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Fig. 3. Inhibitory activity of LA and NAC on HIV-I p24 antigen 
expression in the TNF-t~-stimulated OM 10.1 cultures. Cells were 
pretreated overnight with varying concentrations of LA or NAC. 
Following NF-KB stimulation with 2 ng/ml TNF-t~ for another 72 
h, HIV-1 p24 antigen level was quantitated using solid phase en- 
zyme immunoassay. 
recommended for use in screening other candidate anti-NF- 
~:B agents which can be used to prevent or to limit the pro- 
gression of NF-~cB-mediated diseases uch as AIDS. 
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